SecurityAZN / AstraZeneca Plc
InstitutionJNBA Financial Advisors
Shares300
Value $ 11,000
Related 046353AB4 / Astrazeneca 5.9% Senior Notes 9/15/17
046353AF5 / Astrazeneca Plc 1.95% 09/18/19
046353AG3 / Astrazeneca Plc 4.00% 09/18/42
046353AA6 / Astrazeneca Plc 5.40% Notes 06/01/2014
046353AD0 / Astrazeneca Plc 6.45% Senior Notes 9/15/37
98934KAB6 / Zeneca Wilmington Inc Guaranteed Debentures 7% 11/15/23

JNBA Financial Advisors ownership in AZN / AstraZeneca Plc

July 17, 2018 - JNBA Financial Advisors has filed a 13F-HR form disclosing ownership of 300 shares of AstraZeneca Plc (NYSE:AZN) with total holdings valued at $11,000 USD as of June 30, 2018. JNBA Financial Advisors had filed a previous 13F-HR/A on May 09, 2018 disclosing 300 shares of AstraZeneca Plc at a value of $10,000 USD. This represents a change in shares of 0.00 percent and a change in value of 10.00 percent during the quarter.

Other investors with positions similar to JNBA Financial Advisors include Taylor Wealth Management Partners, Asset Planning Services, Ltd., CT Financial Advisors LLC, Hudson Canyon Investment Counselors Llc, Mercer Capital Advisers, Inc., and Resources Investment Advisors, Inc..

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2018-06-30 13F-HR ASTRAZENECA SPONSORED ADR 046353108 35.00 300 0.00 11 10.00 0 1 10.00
2018-03-31 13F-HR/A-1 ASTRAZENECA SPONSORED ADR 046353108 33.33 300 0.00 10 0.00 0 0 0.00
2018-03-31 13F-HR ASTRAZENECA SPONSORED ADR 046353108 300 300
2017-12-31 13F-HR ASTRAZENECA SPONSORED ADR 046353108 33.33 300 0.00 10 0.00 0 0 0.00
2017-09-30 13F-HR ASTRAZENECA SPONSORED ADR 046353108 33.33 300 0.00 10 0.00 0 0 0.00
2017-06-30 13F-HR ASTRAZENECA SPONSORED ADR 046353108 31.67 300 0.00 10 11.11 0 1 11.11
2017-03-31 13F-HR ASTRAZENECA SPONSORED ADR 046353108 300 9 9 0
2016-12-31 13F-HR ASTRAZENECA SPONSORED ADR 046353108 0 -100.00 0 -100.00 0 0
2016-09-30 13F-HR ASTRAZENECA SPONSORED ADR 046353108 4,902 161 161 0
2016-06-30 13F-HR ASTRAZENECA SPONSORED ADR 046353108 0 -100.00 0 -100.00 0 0
2016-03-31 13F-HR ASTRAZENECA SPONSORED ADR 046353108 126 4

Related SEC Filings

AZN / AstraZeneca Plc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G (Passive Investment)

2018-02-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* ASTRAZENECA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G0593M107 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder o

AZN / AstraZeneca Plc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G (Passive Investment)

2018-02-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* ASTRAZENECA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G0593M107 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder o

AZN / AstraZeneca Plc / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-30 sec.gov
gb0009895292_012918.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) ASTRAZENECA PLC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) B01DCL2 -------------------------------------------------------- (SEDOL Number) December 31, 2017 --------------------------------------------------------

AZN / AstraZeneca Plc / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-30 sec.gov
gb0009895292_012918.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) ASTRAZENECA PLC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) B01DCL2 -------------------------------------------------------- (SEDOL Number) December 31, 2017 --------------------------------------------------------

AstraZeneca SEC SCHEDULE 13G (Passive Acquisition of More Than 5% of Shares)

2017-02-09 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* ASTRAZENECA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G0593M107 (CUSIP Number) December 30, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder o (0-1)

Related News Stories

Healthcare 16-24% Target Net Gains Pace WallStars For October

2018-10-15 seekingalpha
Big pharma drug makers and biotech continued to top the healthcare sector by broker targets. WallStars are distinguished by positive broker target price upsides. (34-0)

3 Large-Cap Pharma Stocks Performing Better Than Industry

2018-10-12 zacks
The Zacks Large-Cap Pharma industry, a 14 medical stock group, has gained 5.4% in the year so far. This industry also features among the top 9% of the 256 Zacks-ranked industries. (9-0)

J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion

2018-10-12 zacks
Janssen, a subsidiary of Johnson & Johnson (JNJ - Free Report) , announced that the FDA has approved the label expansion of its blood thinner, Xarelto. The drug is now approved for reduction in risk of major cardiovascular (“CV”) events including CV death, myocardial infarction (“MI”) and stroke, in patients with chronic coronary or peripheral artery disease (CAD/PAD). (16-0)

PhaseBio IPO: Data To Be Released In 2018 And 2020

2018-10-12 seekingalpha
PhaseBio is a clinical-stage biopharmaceutical company developing treatments for orphan diseases. With a specialization on the cardiopulmonary space, the company has two product candidates, PB2452 and PB1046. (3-0)

Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts

2018-10-11 zacks
On Oct 10, we issued an updated research report on Merrimack Pharmaceuticals, Inc. (MACK - Free Report) . (16-0)



CUSIP: 046353108